Friday, November 13, 2026

Intel +240%, AMD +112%: Global AI Inference Shift Leaves Nvidia Behind in 2026 Rally

Intel has surged 240% year-to-date in 2026 while Nvidia — the world's dominant AI chipmaker — has returned just 15%. The divergence reflects how global AI infrastructure spending is flowing beyond training GPUs into inference-optimised hardware. Markets from Wall Street to Tokyo are repricing chipmakers at the edges of Nvidia's ecosystem.

LM Salvado
LM Salvado

May 12, 2026

Intel +240%, AMD +112%: Global AI Inference Shift Leaves Nvidia Behind in 2026 Rally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Intel stock has surged 240% year-to-date in 2026.1 AMD is up 112%. Micron Technology has gained 162%.1 Nvidia, the dominant AI chip supplier to data centres across the US, Europe, and Asia, has returned just 15%.1

The gap reflects a structural shift in global AI spending. Nvidia's GPU dominance — cemented through contracts with hyperscalers from Amazon to Alibaba — is established and priced in. Markets are now repricing companies on the edges of Nvidia's ecosystem.

AI inference is the driver. Training a model favours Nvidia's high-end GPUs. Running that model — serving queries to billions of users globally — rewards efficiency and lower cost-per-query. CPUs from Intel and AMD compete strongly on inference, particularly where GPU-level parallelism is unnecessary.

AMD doubled its server CPU total addressable market forecast.1 That revision signals real demand, not theoretical opportunity. Across data centres in Frankfurt, Singapore, and Virginia, operators are reconsidering CPU-based inference for cost-sensitive workloads.

Micron's 162% gain reflects its position as a critical supplier to all sides.1 High-bandwidth memory is essential whether a workload runs on a GPU or CPU. Micron ships to Nvidia, Intel, and the hyperscalers building AI infrastructure across every major market. Its rally reflects broad spending, not a single architecture bet.

The pattern has precedent. In the PC era, dominant platform vendors underperformed once their position was priced in. Re-rating moved to component suppliers and adjacent competitors gaining share — a dynamic visible from Seoul's DRAM manufacturers to Silicon Valley's fabless designers.

Nvidia's +15% is not a failure. It reflects a stock already valued for market dominance. Intel's +240% reflects a market repricing a company that lost ground for years and has found renewed relevance in an inference-heavy global AI landscape.

The thesis will be tested in IDC and Gartner server market share reports through end of 2026.1 If AMD's CPU share gains appear in quarterly data, the bifurcation holds. If Nvidia extends its GPU lead into inference workloads globally, the Intel and AMD re-rating may prove temporary.

For now, global semiconductor markets are voting that AI infrastructure build-out benefits the full supply chain — but that Nvidia's upside has already been spent.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com